This question may stray to focus of Biostar a little bit. Still, I believe this regards both cancer research as well as technical bioinformatics.
There are numerous cancer driver genes / mutations that, by definition, frequently appear in certain cancer types and drive tumorigenesis. Many of them have been identified years ago.
However, New driver genes / mutations have continuously emerged from bioinformatic analysis in recent years. As far as my understanding, the most straightforward way to seek for cancer driver is through population frequency. So, is it just because we are able to sequence more tumor samples and obtain greater statistical power these days? Or these are other consideration in this cancer driver discovery field?. If sample size is the only factors here, does this mean that only large collaborative cancer project (with large sample size) is useful in terms of discovering new driver event, and study with smaller sample size stand few chance for that?
A minor question is: I guess to claim the discovery of new cancer events in study, there has be to at least some degrees of elucidation of how this event promotes cancer mechanistically instead of just saying that we observe a event with frequency beyond expectation, right?